Post-transplant lymphoproliferative disease
MONDO:0019088Post-transplant lymphoproliferative disorder (PTLD) is a polyclonal (benign) or clonal (malignant) proliferation of lymphoid cells that develops as a consequence of immunosuppression in a recipient of a solid organ or bone marrow allograft. PTLDs comprise a spectrum ranging from early, Epstein-Barr virus (EBV)-driven polyclonal lymphoid proliferations to EBV-positive or EBV- negative lymphomas of predominantly B-cell or less often T-cell type. (WHO, 2001)
Also known as: PTLD, post-transplant lymphoproliferative disorder
28 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
New vaccine aims to stop Virus-Linked cancers in organ transplant patients
⭐️ VACCINE ⭐️ Recruiting nowThis early-stage trial tests a vaccine called OSU-2131, designed to help the immune system fight Epstein-Barr virus (EBV). EBV can cause cancers in people who have weakened immune systems, such as those awaiting organ transplants. The study includes healthy volunteers and transpl…
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 03, 2026 23:00 UTC
-
Cancer drug nivolumab takes on EBV-Linked tumors in new trial
Disease control Recruiting nowThis phase 2 trial tests whether the drug nivolumab can slow or stop the growth of Epstein-Barr virus (EBV)-positive lymphoproliferative disorders and non-Hodgkin lymphomas. About 40 people aged 12 and older whose cancers have not responded to standard therapy will receive nivolu…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Blood test may spare some transplant patients from chemo
Disease control Recruiting nowThis study tests whether a blood test (ctDNA) can help doctors choose the right treatment for people with a type of lymphoma that happens after an organ transplant (PTLD). About 30 participants will be split into low-risk and high-risk groups. Low-risk patients will get only the …
Phase: PHASE2 • Sponsor: Jennifer Amengual • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Donor immune cells take on Virus-Linked cancer after transplant
Disease control Recruiting nowThis phase 3 trial tests tabelecleucel, a cell therapy made from donor immune cells, in 115 organ or stem cell transplant patients who developed a rare cancer (EBV+ PTLD) after standard treatment failed. The goal is to see if it can shrink tumors and improve outcomes. Participant…
Phase: PHASE3 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug duo aims to tackle Transplant-Related lymphoma
Disease control Recruiting nowThis study tests whether combining two antibody drugs, tafasitamab and rituximab, can effectively treat a type of lymphoma that sometimes occurs after an organ transplant. About 28 adults who have developed this condition will receive the drug combination. The main goal is to see…
Phase: PHASE2 • Sponsor: Timothy Voorhees • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New cell therapy targets EBV-Linked cancers in early trial
Disease control Recruiting nowThis early-phase study is testing an experimental cell therapy called EBV-AST for people with Epstein-Barr virus (EBV)-related lymphoproliferative disorders, including certain blood cancers and post-transplant complications. About 18 adults will receive up to 3 infusions of the t…
Phase: PHASE1, PHASE2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Immune cells take aim at Post-Transplant virus
Disease control Recruiting nowThis early-stage study tests a new treatment using specially grown immune cells (EBV-AST cells) to fight EBV infections in people who have had a stem cell transplant. The trial will enroll 18 adults with persistent EBV in their blood. Researchers will test three different doses t…
Phase: PHASE1, PHASE2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New immune cell therapy takes on virus after transplant
Disease control Recruiting nowThis early-phase study tests a new treatment for Epstein-Barr virus (EBV) that can occur after a stem cell transplant. The treatment uses specially engineered immune cells (EBV-TCR-T cells) to find and destroy virus-infected cells. Up to 18 adult patients who have persistent EBV …
Phase: PHASE1, PHASE2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New cell prep method aims to tame transplant complications in kids
Disease control AVAILABLEThis study offers a special way to prepare donor stem cells for children and teens under 22 who need a transplant but lack a perfectly matched sibling donor. The method uses the CliniMACS® system to remove certain immune cells, which may help reduce the risk of graft-versus-host …
Sponsor: Victor Aquino • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Nerve check may predict transplant complication risk
Knowledge-focused Recruiting nowThis study looks at 60 people getting a stem cell transplant to see if their autonomic nervous system (which controls things like heart rate and sweating) can help predict a serious complication called graft-versus-host disease (GvHD). Participants will have simple nerve tests be…
Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC